Anna Polakiewicz-Gilowska

Anna Polakiewicz-Gilowska

Auto-generated profile, based on publicly available information

Anna Polakiewicz-Gilowska

Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch Breast Cancer Center Gliwice 44-102

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
ŁGŁukasz Gilowski
Łukasz Gilowski
RWRafał Wiench
Rafał Wiench
APAnna Polakiewicz-Gilowska
Anna Polakiewicz-Gilowska
KDKatarzyna Dwornicka
Katarzyna Dwornicka

19 August 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
MPMałgorzata Pieniążek
Małgorzata Pieniążek
APAnna Polakiewicz-Gilowska
Anna Polakiewicz-Gilowska
MLManuela Las-Jankowska
Manuela Las-Jankowska
JWJakub Wronowicz
Jakub Wronowicz
MJMichał Jarza̧b
Michał Jarza̧b
Miroslawa PüsküllüoğluMiroslawa Püsküllüoğlu
Miroslawa Püsküllüoğlu
Background: Body mass index (BMI) and weight change are commonly explored as prognostic factors in breast cancer. However, their impact on outcomes with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) remains poorly defined. Objectives: To evaluate the association between baseline BMI, weight change during treatment, and clinical outcomes—including survival and adverse events (AEs)—in a real-world Polish cohort of women with mTNBC receiving SG therapy. Design: A retrospective, multicenter cohort study. Methods: A total of 83 women with mTNBC treated with SG across four oncology centers in Poland between August 2021 and September 2024 were analyzed. BMI was categorized by World Health Organization (WHO) criteria: underweight (BMI < 18.5 kg/m 2 ), normal weight (18.5–24.9 kg/m 2 ), overweight (25.0–29.9 kg/m 2 ), and obese (⩾30.0 kg/m 2 ). Weight changes were recorded from baseline to last treatment cycle, indicating loss or gain. Median progression-free survival (mPFS) and median overall survival (mOS) were assessed using multivariate Cox regression models (significance level α = 0.05). AEs were classified, using the National Cancer Institute Common Terminology Criteria for AEs (NCI-CTCAE), version 5.0, and compared across BMI and weight stability categories. Results: The mPFS was 4.07 months (95% CI: 3.05–6.18), and the mOS was 8.01 months (95% CI: 6.05–9.75). The median follow-up time was 7.42 months (95% CI: 6.07–8.96). Neither baseline BMI nor weight change significantly influenced PFS (BMI p = 0.09, weight change: p = 0.68) or OS (BMI: p = 0.09, weight change: p = 0.21). No BMI categories predicted disease progression or mortality. In addition, there were no significant differences in the frequency or severity of AEs (neutropenia, diarrhea, nausea, or hepatic toxicity) based on BMI or weight stability ( p > 0.05). Conclusion: In this real-world Polish cohort of women with mTNBC treated with SG, neither BMI nor weight changes were prognostic indicators for survival or AE profiles. These findings underscore the necessity for identifying more reliable prognostic biomarkers in this patient population.

19 November 2024 in Radiotherapy and Oncology
Verified
Journal Article
Open access
Marcin KubeczkoMarcin Kubeczko
Marcin Kubeczko
DGDorota Gabryś
Dorota Gabryś
JRJustyna Rembak-Szynkiewicz
Justyna Rembak-Szynkiewicz
DGDonata Gräupner
Donata Gräupner
APAnna Polakiewicz-Gilowska
Anna Polakiewicz-Gilowska
MJMichał Jarząb
Michał Jarząb
Background: In patients diagnosed with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, bone metastases emerge as the primary site of significant tumor burden. Cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors are the gold standard in this clinical scenario, while radiotherapy (RT) represents a valuable addition. However, data on the efficacy of this combination remain scarce. We aimed to evaluate efficacy of RT in bone metastatic breast cancer patients treated with CDK4/6 inhibitors. Materials and methods: 398 patients (pts) with ER-positive HER2-negative breast cancer with bone metastases treated with CDK4/6i between 2018-2024 were analyzed. A total of 114 pts received 177 bone RT concurrently with CDK4/6i or within 6 months before CDK4/6i initiation, including 34 courses of stereotactic-body RT and 143 courses of conventional RT. Results: The median progression-free survival (PFS) in pts who received bone RT was 31.0 months, compared to 26.3 months in pts without bone RT. The 2-y PFS for pts with bone RT was 57.1 % [95 % CI: 46.3-66.6 %] vs. 53.2 % [95 % CI: 46.3-59.6 %] for patients without bone RT (p = 0.51). The median overall survival (OS) for pts who received bone RT was 49.1 months, compared to 40.5 months for pts without bone RT. The 3-y OS for pts with bone RT was 63.7 % [95 % CI: 51.5-73.5 %] vs. 55.0 % [95 % CI 46.6-62.6 %] for pts without bone RT (p = 0.50). The 3-y local control for irradiated patients was 86.9 % [95 % CI 72.2-94.1 %]. Conclusions: In this study, we present the largest cohort published to date of breast cancer patients who received CDK4/6i alongside bone-directed RT. Although the observed differences in survival were not statistically significant, RT remains a viable treatment modality in metastatic breast cancer in some patients.

1 January 2012 in Contemporary Oncology
Verified
Journal Article
Open access
ENElżbieta Nowara
Elżbieta Nowara
ABAgnieszka Boratyn-Nowicka
Agnieszka Boratyn-Nowicka
APAnna Polakiewicz-Gilowska
Anna Polakiewicz-Gilowska
ADAnna Drosik
Anna Drosik
MKMagdalena Kustra
Magdalena Kustra
JHJoanna Huszno
Joanna Huszno
Gastric cancer is one of the most frequent neoplasms. Although the incidence of gastric cancer worldwide has declined, there is still high mortality. Treatment of inoperable disease is under evaluation in clinical trials. In palliative treatment chemotherapy containing cisplatin and...

20 July 2026 in The Oncologist
Verified
Journal Article
Open access
AKAleksandra Konieczna
Aleksandra Konieczna
MPMałgorzata Pieniążek
Małgorzata Pieniążek
JŻJustyna Żubrowska
Justyna Żubrowska
APAnna Polakiewicz-Gilowska
Anna Polakiewicz-Gilowska
RSRenata Soumarová
Renata Soumarová
MPMirosława Püsküllüoğlu
Mirosława Püsküllüoğlu
Background: Older adults with metastatic triple-negative breast cancer (mTNBC) remain underrepresented in clinical trials. Although sacituzumab govitecan (SG) improved outcomes in the phase III ASCENT trial, real-world data in older populations remain limited. Materials and methods: We conducted a retrospective, multinational study across 18 oncology centers in Central Europe, including patients with mTNBC treated with SG between August 2021 and May 2025. Patients were stratified by age at SG initiation: <65 vs ≥65 years. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), treatment modifications, and safety. Results: Among 303 patients, 76 (25.1%) were aged ≥65 years. Older patients had more comorbidities, more prior palliative treatment lines, and more frequent ECOG performance status ≥1. In unadjusted analyses, patients aged ≥65 years had longer median OS (12.8 vs 10.9 months; HR, 0.70; 95% CI, 0.49-0.99; P = 0.045) and PFS (5.4 vs 4.1 months; HR, 0.73; 95% CI, 0.54-0.97; P = 0.031). ORR, DCR, treatment modifications, and grade ≥3 neutropenia were comparable between groups. In multivariable analyses, age was not independently associated with OS or PFS. Conclusion: In this selected real-world cohort, patients aged ≥65 years who received SG had outcomes at least comparable to those of younger patients, without an apparent excess severe toxicity. Survival differences were likely influenced by baseline disease characteristics and patient selection rather than chronological age alone.